Crizotinib clinical trials
Also written Xalkori, PF-02341066 and PF-2341066.
How each study uses Crizotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Crizotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Aug 2011 · XALKORI · NDA 202570 (FDA, Drugs@FDA)
- European Union
- 23 Oct 2012 · Xalkori · EMEA/H/C/002489 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
79 studies that test it; most in 2015 (11)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 3 |
| 2010 | 10 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 7 |
| 2014 | 8 |
| 2015 | 11 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 31 · Other 48
Pfizer (29) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (4) · Hunan Province Tumor Hospital (3) · Samsung Medical Center (2) · ECOG-ACRIN Cancer Research Group (1) · Hoffmann-La Roche (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Palbociclib (7) · Alectinib (7) · Dasatinib (6) · Sunitinib (6) · Axitinib (6) · Erlotinib (6) · Nivolumab (4) · Trastuzumab (4)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 10 phase 3 studies under way
Crizotinib is the comparator. A study of two new drugs counts under both.
- 1Repotrectinib · Bristol-Myers Squibb · next primary completion Feb 2027
- 1Entrectinib · Hoffmann-La Roche
- 1Lorlatinib · Pfizer
- 1Ensartinib · Xcovery Holdings, Inc.
- 1Deulorlatinib · Shenzhen TargetRx, Inc.
- 1Iruplinalkib · Qilu Pharmaceutical Co., Ltd.
- 1Fudotinib · Guangzhou JOYO Pharma Co., Ltd · next primary completion Dec 2028
- 1Ficonalkib · Shouyao Holdings (Beijing) Co. LTD
Reaching primary completion within a year · 4
Studies that test Crizotinib.
- Dec 2026Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationPhase 2 · Hunan Province Tumor Hospital
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses Crizotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 79
- Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaRecruitingPhase 3IDEAYA BiosciencesNCT07804186Written as Crizotinib (Xalkori)
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT04693468Written as Crizotinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Crizotinib
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Crizotinib
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04423185Written as Crizotinib 250 MG
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingPhase 2Hunan Province Tumor HospitalNCT04322890Written as Crizotinib 250 MG
- ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaRecruitingPhase 2Hunan Province Tumor HospitalNCT05014464Written as Crizotinib
- Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCRecruitingPhase 2Hunan Province Tumor HospitalNCT04322578Written as Crizotinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Crizotinib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Crizotinib
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439266Written as Crizotinib
- Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439253Written as Crizotinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Crizotinib
- Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06360575Written as Crizotinib
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedPhase 3Hoffmann-La RocheNCT03194893Written as Crizotinib
- Study of Crizotinib for ROS1 and MET Activated Lung CancerCompletedPhase 2University Health Network, TorontoNCT04084717Written as Crizotinib
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935Written as Crizotinib
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03737994Written as Crizotinib
- Crizotinib Continuation Clinical StudyActive, not recruitingPhase 4PfizerNCT05160922Written as crizotinib
- Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06357975Written as Crizotinib
See all 79 studies that test Crizotinib →
Given beside what is tested · 14 — Crizotinib is usual care or a partner of the new treatment
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsRecruitingPhase 1/2IDEAYA BiosciencesNCT03947385Written as Crizotinib
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNot applicableNational Cancer Institute (NCI)NCT02194738Written as Crizotinib
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingPhase 2/3IDEAYA BiosciencesNCT05987332Written as Crizotinib
- Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompletedPhase 2Royal Marsden NHS Foundation TrustNCT03620643Written as Crizotinib Oral Capsule [Xalkori]
- Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical TrialsCompletedNot applicablePfizerNCT00828919Written as crizotinib
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibCompletedPhase 1/2Astex Pharmaceuticals, Inc.NCT01712217Written as Crizotinib
- Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaCompletedPhase 1Children's Oncology GroupNCT01606878Written as Crizotinib
- Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedPhase 1/2PfizerNCT02584634Written as Crizotinib
- MEK and MET Inhibition in Colorectal CancerCompletedPhase 1University of OxfordNCT02510001Written as PF-02341066
- A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Bristol-Myers SquibbNCT02574078Written as Crizotinib
- Lorlatinib Combinations in Lung CancerStatus unknownPhase 1/2Massachusetts General HospitalNCT04292119Written as Crizotinib
- S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibTerminatedPhase 2SWOG Cancer Research NetworkNCT02134912Written as crizotinib
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerTerminatedPhase 1National Cancer Institute (NCI)NCT01441128Written as PF-02341066/PF-00299804
- Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaStatus unknownPhase 2Shanghai Jiao Tong University School of MedicineNCT02836847Written as Crizotinib
As the comparator · 15 — what is tested is compared with Crizotinib
- A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 3Guangzhou JOYO Pharma Co., LtdNCT07816380Written as Crizotinib Capsules
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsRecruitingPhase 3Nuvation Bio Inc.NCT06564324Written as Crizotinib
- A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNot yet recruitingPhase 3Shouyao Holdings (Beijing) Co. LTDNCT06254599Written as Crizotinib Capsules
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingPhase 3Xuanzhu Biopharmaceutical Co., Ltd.NCT05204628Written as Crizotinib
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Active, not recruitingPhase 3Bristol-Myers SquibbNCT06140836Written as Crizotinib
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingPhase 3Hoffmann-La RocheNCT04603807Written as Crizotinib
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Hoffmann-La RocheNCT02838420Written as Crizotinib
- A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedPhase 3Hoffmann-La RocheNCT02075840Written as Crizotinib
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCActive, not recruitingPhase 3PfizerNCT03052608Written as Crizotinib
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 3Xcovery Holdings, Inc.NCT02767804Written as crizotinib
- TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 3Shenzhen TargetRx, Inc.NCT06082635Written as Crizotinib
- A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsCompletedPhase 1/2PfizerNCT01970865Written as Crizotinib
- Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT04632758Written as crizotinib
- ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedPhase 3Ariad PharmaceuticalsNCT02737501Written as Crizotinib
- Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)Status unknownPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04009317Written as Crizotinib
Codes
What other systems call Crizotinib · ClinicalTrials.gg INT006744
- MeSH (NLM) D000077547CrizotinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 53AH36668SCRIZOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1148495Confirmed FDA, Wikidata
- Wikidata Q5186964crizotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74061CrizotinibOne source FDA
- DrugBank DB08865One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077547 | Crizotinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 53AH36668S | CRIZOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1148495 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5186964 | crizotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74061 | Crizotinib | One source FDA |
| DrugBank | DB08865 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.